Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

There are some, right? Come on, a few? No? In any case, I shall be doing my weekly gig on CNN’s Headline News at 1.15 PM, EST. My subject? NitroMed’s new drug BiDil, which shows remarkable efficacy in treating congestive heart failure in African Americans. NitroMed wants to specifically market the drug to blacks. But the whole idea has race activists understandably worried, and scientists who know something about drugs and genetic populations believe that race is far too vague and inaccurate a category to be useful in drug discovery. In the case of BiDil, as Technology Review’s executive editor David Rotman explained back in Race and Medicine in April, it is much more likely that BiDil would benefit any patient suffering from congestive heart failure as the result of hypertension. Which happens to be the most common reason African Americans have heart disease.

1 comment. Share your thoughts »

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me